These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23257221)

  • 1. Pretreatment antiretroviral exposure from recreational use.
    Grelotti DJ; Closson EF; Mimiaga MJ
    Lancet Infect Dis; 2013 Jan; 13(1):10-2. PubMed ID: 23257221
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral therapy: treatment-experienced individuals.
    Calvo KR; Daar ES
    Infect Dis Clin North Am; 2014 Sep; 28(3):439-56. PubMed ID: 25151565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].
    ;
    Dtsch Med Wochenschr; 2009 Jan; 134 Suppl 1():S4-15. PubMed ID: 19172554
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.
    Reynolds SJ; Laeyendecker O; Nakigozi G; Gallant JE; Huang W; Hudelson SE; Quinn TC; Newell K; Serwadda D; Gray RH; Wawer MJ; Eshleman SH
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1739-44. PubMed ID: 22443282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New antiretroviral drugs and approaches to HIV treatment.
    Paredes R; Clotet B
    AIDS; 2003; 17 Suppl 4():S85-96. PubMed ID: 15080184
    [No Abstract]   [Full Text] [Related]  

  • 6. [Mutations resulting in resistence of antiretroviral drugs in HIV-infected patients].
    Cabrera C; Clotet B
    Med Clin (Barc); 2005 Apr; 124(16):618-9. PubMed ID: 15871779
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antiviral treatment regimens].
    Esser S
    Hautarzt; 2006 Nov; 57(11):961-2, 964-8. PubMed ID: 17053925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV in 2010: potent antiretroviral drugs treat and sensitive assays monitor the infection; but there remain outstanding issues.
    Antonelli G
    Clin Microbiol Infect; 2010 Oct; 16(10):1509-10. PubMed ID: 20854461
    [No Abstract]   [Full Text] [Related]  

  • 9. Baseline antiretroviral resistance and clinical outcomes in an urban HIV clinic.
    Klibanov OM; Dolder CR; Assefa F; Ekwonu TJ
    AIDS Patient Care STDS; 2013 Apr; 27(4):205-7. PubMed ID: 23514132
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral therapy: a primer for dermatologists.
    Kim HN; Harrington RD
    Dermatol Clin; 2006 Oct; 24(4):537-47, vii. PubMed ID: 17010782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.
    van Zyl GU; Frenkel LM; Chung MH; Preiser W; Mellors JW; Nachega JB
    AIDS; 2014 Nov; 28(18):2643-8. PubMed ID: 25493592
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052.
    Palumbo PJ; Fogel JM; Hudelson SE; Wilson EA; Hart S; Hovind L; Piwowar-Manning E; Wallis C; Papathanasopoulos MA; Morgado MG; Saravanan S; Tripathy S; Eron JJ; Gallant JE; McCauley M; Gamble T; Hosseinipour MC; Kumarasamy N; Hakim JG; Pilotto JH; Kumwenda J; Akelo V; Godbole SV; Santos BR; Grinsztejn B; Panchia R; Chariyalertsak S; Makhema J; Badal-Faesen S; Chen YQ; Cohen MS; Eshleman SH
    J Acquir Immune Defic Syndr; 2018 Apr; 77(5):484-491. PubMed ID: 29293156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral reduction: is it time to rethink the unthinkable?
    Colasanti J; Marconi VC; Taiwo B
    AIDS; 2014 Apr; 28(7):943-7. PubMed ID: 24401641
    [No Abstract]   [Full Text] [Related]  

  • 14. Utility of interrupting antiretroviral treatment before HIV drug resistance testing in patients with persistently detectable low-level viremia.
    Sirvent JL; Socas MM; Calzadilla CH; Lirola AM; Valls MR
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):111-3. PubMed ID: 16123693
    [No Abstract]   [Full Text] [Related]  

  • 15. [Transmission of antiretroviral drug resistant strains in patients diagnosed with human immunodeficiency virus infection in Gran Canaria in the period 2009-2012].
    Chamizo-López FJ; Gilarranz-Luengo R; Hernández-Febles M; Pena-López MJ
    Enferm Infecc Microbiol Clin; 2014 Dec; 32(10):695-6. PubMed ID: 24666476
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.
    Pierone G; Urban T; Martin A; Mieras J; Kantor C
    HIV Clin Trials; 2008; 9(2):140-1. PubMed ID: 18474499
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiretroviral drugs in HIV-infected children.
    Viganò A; Manfredini V; Penagini F; Giacomet V; Zuccotti GV
    Pharmacol Res; 2011 Jul; 64(1):1-3. PubMed ID: 21255650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk?
    Mangioni D; Muscatello A; Sabbatini F; Soria A; Rossi M; Bisi L; Squillace N; De Grandi C; Gori A; Bandera A
    Clin Infect Dis; 2014 Dec; 59(11):1655-6. PubMed ID: 25156113
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial commentary: monitoring early warning indicators for HIV drug resistance in South Africa: challenges and opportunities.
    Rossouw TM
    Clin Infect Dis; 2014 Jun; 58(11):1615-7. PubMed ID: 24585563
    [No Abstract]   [Full Text] [Related]  

  • 20. Darunavir: after multiple antiretroviral treatment failure: another option.
    Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18629967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.